์ฝ๋ ๋ฐฉ๋ฒ: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease ...
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel ...
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
--BridgeBio Pharma, Inc. and Maze Therapeutics today announced the establishment of a joint venture, Contour Therapeutics, focused on transforming and advancing breakthrough precision medicine ...
Maze Therapeutics CEO Jason Coloma will present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2025. Quiver AI Summary Maze Therapeutics, Inc., a biopharmaceutical company ...
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
Maze Therapeutics, Inc. ๊ฒฝ์์ฌ ๋ฐ ๋์ข ์ ๊ณ ๋ถ์ - Life Sciences ์นํฐ
AI ๊ธฐ๋ฐ ์์ธก๊ณผ ์ฃผ์ ์ฌ๋ฌด ์งํ๋ฅผ ํตํด Life Sciences ๋ถ๋ฌธ์ ์ ๊ณ ๋๋ฃ ๋ฐ ๊ฒฝ์์ฌ์ Maze Therapeutics, Inc.์ ๋น๊ต ๋ถ์ํฉ๋๋ค.
์์ฃผ ๋ฌป๋ ์ง๋ฌธ - Maze Therapeutics, Inc. ์ฌ๊ณ ์์ธก
Maze Therapeutics, Inc. ์ฃผ์ ์์ธก์ ์ผ๋ง๋ ์ ํํฉ๋๊น?
Our AI model demonstrates 57% historical accuracy for MAZE predictions, based on advanced machine learning algorithms trained on over 10 years of market data.